Literature DB >> 11588995

Pre- and postnatal enzyme analysis for infantile, late infantile and adult neuronal ceroid lipofuscinosis (CLN1 and CLN2).

O P Van Diggelen1, J L Keulemans, W J Kleijer, S Thobois, C Tilikete, Y V Voznyi.   

Abstract

The recent development of simple, fluorogenic enzyme assays for infantile and late infantile neuronal ceroid lipofuscinosis (INCL and LINCL; CLN1 and CLN2) has greatly facilitated the diagnostic process for these diseases. In leucocytes and fibroblasts from INCL (n = 38) patients we found profound deficiencies of palmitoyl-protein thioesterase I (PPT1), the residual activity was < 5% of mean control activity. In fibroblasts from LINCL patients we found a similar deficiency of tripeptidyl-peptidase I activity (TPP-I), with < 2% activity in 16 patients. The residual TPP-I activity in leucocytes from LINCL patients seemed substantially higher. We also showed the feasibility of reliable prenatal enzyme analysis. In five first-trimester and two second-trimester prenatal analyses for INCL, four affected foetuses were detected (PPT activity 3-6%). Two first trimester pregnancies at risk for LINCL were analysed and a clear TPP-I deficiency was detected in both cases (TPP-I activity 3-4%). The first patient with adult neuronal ceroid lipofuscinosis (ANCL) due to a deficiency of PPT is presented; her present age is 53 years and the onset of the disease was at 38 years with psychiatric symptoms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588995     DOI: 10.1053/ejpn.2000.0460

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  8 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Prospects for stem cell therapy in neuronal ceroid lipofuscinosis.

Authors:  Michael C Kruer; David A Pearce; Paul J Orchard; Robert D Steiner
Journal:  Regen Med       Date:  2013-09       Impact factor: 3.806

Review 3.  [Adult-onset neuronal ceroid lipofuscinosis].

Authors:  H J Gdynia; A D Sperfeld; A C Ludolph
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

4.  Lysosomal proteome analysis reveals that CLN3-defective cells have multiple enzyme deficiencies associated with changes in intracellular trafficking.

Authors:  Carolin Schmidtke; Stephan Tiede; Melanie Thelen; Reijo Käkelä; Sabrina Jabs; Georgia Makrypidi; Marc Sylvester; Michaela Schweizer; Ingke Braren; Nahal Brocke-Ahmadinejad; Susan L Cotman; Angela Schulz; Volkmar Gieselmann; Thomas Braulke
Journal:  J Biol Chem       Date:  2019-04-30       Impact factor: 5.157

5.  The LINCE Project: A Pathway for Diagnosing NCL2 Disease.

Authors:  Daniel Rodrigues; Maria José de Castro; Pablo Crujeiras; Anna Duat-Rodriguez; Ana Victoria Marco; Mireia Del Toro; María L Couce; Cristóbal Colón
Journal:  Front Pediatr       Date:  2022-03-29       Impact factor: 3.418

Review 6.  Neuronal ceroid lipofuscinosis in the South American-Caribbean region: An epidemiological overview.

Authors:  Guillermo Guelbert; Ana Clara Venier; Ines Adriana Cismondi; Adriana Becerra; Juan Carlos Vazquez; Elmer Andrés Fernández; Ana Lucía De Paul; Norberto Guelbert; Ines Noher; Favio Pesaola
Journal:  Front Neurol       Date:  2022-08-12       Impact factor: 4.086

7.  Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1)--distinct characteristics in neurons.

Authors:  Annina Lyly; Carina von Schantz; Tarja Salonen; Outi Kopra; Jani Saarela; Matti Jauhiainen; Aija Kyttälä; Anu Jalanko
Journal:  BMC Cell Biol       Date:  2007-06-12       Impact factor: 4.241

Review 8.  The CLN3 gene and protein: What we know.

Authors:  Myriam Mirza; Anna Vainshtein; Alberto DiRonza; Uma Chandrachud; Luke J Haslett; Michela Palmieri; Stephan Storch; Janos Groh; Niv Dobzinski; Gennaro Napolitano; Carolin Schmidtke; Danielle M Kerkovich
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.